Management and Clinical Outcomes of Breast Cancer in Women Diagnosed with Hereditary Cancer Syndromes in a Clinic-Based Sample from Colombia
Authors:
- María Carolina Sanabria-SalasMSMaría Carolina Sanabria-Salas
- Ana Pedroza-DuranAPAna Pedroza-Duran
- Sandra E. Díaz-CasasSDSandra E. Díaz-Casas
- Marcela Nuñez LemusMLMarcela Nuñez Lemus
- Carlos F. Grillo-ArdilaCGCarlos F. Grillo-Ardila
- Ximena Briceño-MoralesXBXimena Briceño-Morales
- Mauricio García-MoraMGMauricio García-Mora
- Javier Ángel-AristizábalJÁJavier Ángel-Aristizábal
- Iván Fernando Mariño LozanoILIván Fernando Mariño Lozano
- Raúl Alexis Suarez RodríguezRRRaúl Alexis Suarez Rodríguez
- Luis Hernán Guzmán AbisaabLALuis Hernán Guzmán Abisaab
Open Access
Abstract
This study aimed to investigate prognosis and survival differences in 82 breast cancer patients with germline pathogenic/likely pathogenic variants (PVs) treated and followed at the Breast Unit of the Instituto Nacional de Cancerología, Colombia (INC-C) between 2018 and 2021. Median age at diagnosis was 46 years, with 62.2% presenting locally advanced tumors, 47.6% histological grade 3, and 35.4% with triple-negative breast cancer (TNBC) subtype. Most carriers, 74.4% (61/82), had PVs in known breast cancer susceptibility genes (i.e., “associated gene carriers” group, considered inherited breast cancer cases): BRCA2 (30), BRCA1 (14), BARD1 (4), RAD51D (3), TP53 (2), PALB2 (2), ATM (2), CHEK2 (1), RAD51C (1), NF1 (1), and PTEN (1). BRCA1-2 represented 53.7%, and homologous recombination DNA damage repair (HR-DDR) genes associated with breast cancer risk accounted for 15.9%. Patients with PVs in non-breast-cancer risk genes were combined in a different category (21/82; 25.6%) (i.e., “non-associated gene carriers” group, considered other breast cancer cases). Median follow-up was 38.1 months, and 24% experienced recurrence, with 90% being distant. The 5-year Disease-Free Survival (DFS) for inherited breast cancer cases was 66.5%, and for other breast cancer cases it was 88.2%. In particular, for carriers of PVs in the BRCA2 gene, it was 37.6%. The 5-year Overall Survival (OS) rates ranged from 68.8% for those with PVs in BRCA2 to 100% for those with PVs in other HR-DDR genes. Further studies are crucial for understanding tumor behavior and therapy response differences among Colombian breast cancer patients with germline PVs.Keywords
Funding Information
- Program for the Creation of a National Network of Hereditary Cancer in Colombia, INC-C (C19990300218, C19990300210, C41030617-303)
- Institutional Program for the Identification and Management of Families with Suspected Hereditary Cancer, INC-C (C19990300218, C19990300210, C41030617-303)
- Oncological outcomes of patients with high or moderate penetrance genetic variants associated with hereditary breast cancer syndrome at the Breast Unit of the INC-C between 2018 and 2021, INC-C (C19990300218, C19990300210, C41030617-303)
This publication has 58 references indexed in Scilit:
- Variant curation and interpretation in hereditary cancer genes: An institutional experience in Latin AmericaMolecular Genetics & Genomic Medicine, 2023
- Clinical Utility of Universal Germline Genetic Testing for Patients With Breast CancerJAMA Network Open, 2022
- Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysisBreast Cancer, 2021
- Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer SyndromeJAMA Oncology, 2021
- Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriersBreast Cancer Research and Treatment, 2019
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline TestingJAMA, 2017
- A multi-gene panel study in hereditary breast and ovarian cancer in ColombiaFamilial Cancer, 2017
- Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic reviewThe American Journal of Surgery, 2016
- Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from CubaFamilial Cancer, 2008
- Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from BrazilBreast Cancer Research and Treatment, 2006